by Joe Kunkle | Jul 1, 2019
The Pfizer (PFE) deal for Array (ARRY) was one of the most interesting deals as it came at a strong 60% premium and options activity in ARRY was well-positioned for the move. Biotech M&A should remain a theme as a lot of the larger companies are...
Please login to continue reading this article.
Options Hawk Max
$399 | 30 days
More About this Plan
Options Hawk Elite
$199 | 30 days
